HAEM5:Volunteer Assignments and Opportunities: Difference between revisions
| [unchecked revision] | [unchecked revision] |
No edit summary |
No edit summary |
||
| Line 1,700: | Line 1,700: | ||
|- | |- | ||
|[[HAEM5:T-cell/histiocyte-rich large B-cell lymphoma|T-cell/histiocyte-rich large B-cell lymphoma]]||Disease|| || || || || ||GC|| || | |[[HAEM5:T-cell/histiocyte-rich large B-cell lymphoma|T-cell/histiocyte-rich large B-cell lymphoma]]||Disease|| || || || || ||GC|| || | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements]]||Disease|| || || || || ||GC|| || | |[[HAEM5:Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements]]||Disease|| || || || || ||GC|| || | ||
| | |High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements | ||
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland | |Kate Berry, MBBS, BBus (Hons), Pathology Queensland | ||
| | |Complete | ||
| | |24/02/2022 | ||
| | | | ||
|- | |- | ||
|[[HAEM5:ALK-positive large B-cell lymphoma|ALK-positive large B-cell lymphoma]]||Disease|| || || || || ||GC|| || | |[[HAEM5:ALK-positive large B-cell lymphoma|ALK-positive large B-cell lymphoma]]||Disease|| || || || || ||GC|| || | ||
| | |ALK-Positive Large B-cell Lymphoma | ||
|Manando Nakasaki, MD, PhD (University of California, Irvine) Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine) | |Manando Nakasaki, MD, PhD (University of California, Irvine) Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine) | ||
|Pending | |||
| | | | ||
| | |Nakasaki Manando removed March 2022 due to no progress/contact 1y. Added Nakasaki Manando back n 8/29/22 based on newer email communication (Jennelle's note). 2021 template added. FQR emailed Manando on 4/12/23 | ||
|- | |- | ||
|[[HAEM5:Large B-cell lymphoma with IRF4 rearrangement|Large B-cell lymphoma with IRF4 rearrangement]]||Disease|| || || || || ||GC|| || | |[[HAEM5:Large B-cell lymphoma with IRF4 rearrangement|Large B-cell lymphoma with IRF4 rearrangement]]||Disease|| || || || || ||GC|| || | ||
| | |Large B-cell Lymphoma with IRF4 Rearrangement | ||
| | |Afia Hasnain, MBBS, PhD | ||
| | |Complete | ||
| | |5/26/2021 | ||
| | | | ||
|- | |- | ||
|[[HAEM5:High grade B-cell lymphoma with 11q aberrations|High grade B-cell lymphoma with 11q aberrations]]||Disease|| || || || || ||GC|| || | |[[HAEM5:High grade B-cell lymphoma with 11q aberrations|High grade B-cell lymphoma with 11q aberrations]]||Disease|| || || || || ||GC|| || | ||
| | |Burkitt-Like Lymphoma with 11q Aberration | ||
|Lauren Shealy, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina | |Lauren Shealy, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina | ||
| | |Comlete | ||
| | |27/01/2022 | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Lymphomatoid granulomatosis|Lymphomatoid granulomatosis]]||Disease|| || || || || ||GC|| || | |[[HAEM5:Lymphomatoid granulomatosis|Lymphomatoid granulomatosis]]||Disease|| || || || || ||GC|| || | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:EBV-positive diffuse large B-cell lymphoma|EBV-positive diffuse large B-cell lymphoma]]||Disease|| || || || || ||GC|| || | |[[HAEM5:EBV-positive diffuse large B-cell lymphoma|EBV-positive diffuse large B-cell lymphoma]]||Disease|| || || || || ||GC|| || | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Diffuse large B-cell lymphoma associated with chronic inflammation|Diffuse large B-cell lymphoma associated with chronic inflammation]]||Disease|| || || || || ||GC|| || | |[[HAEM5:Diffuse large B-cell lymphoma associated with chronic inflammation|Diffuse large B-cell lymphoma associated with chronic inflammation]]||Disease|| || || || || ||GC|| || | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Fibrin-associated large B-cell lymphoma|Fibrin-associated large B-cell lymphoma]]||Disease|| || || || || ||GC|| || | |[[HAEM5:Fibrin-associated large B-cell lymphoma|Fibrin-associated large B-cell lymphoma]]||Disease|| || || || || ||GC|| || | ||